Avanos Medical has acquired Nexus Medical for an undisclosed amount, bringing Nexus's innovative anti-reflux needleless connector technology under its ownership. This corporate acquisition marks a strategic expansion for Avanos Medical in the critical medical device sector, underscoring its commitment to advancing patient care solutions.
Nexus Medical is renowned for its advanced CVAD needleless connector devices and anti-reflux IV infusion technology, prominently featuring its TKO system. This specialized technology is engineered to safely link patient care with innovative solutions, notably by reducing catheter occlusions. Nexus's TKO technology, containing a bidirectional, pressure-sensitive diaphragm, has been clinically shown to produce the least amount of reflux compared to other needleless connectors, and studies demonstrate a sustained 69% reduction in CVAD occlusions over five years. Its TKO 6P-HV solution, specifically designed for home infusion, has proven effective in preventing occlusions, thereby reducing the need for alteplase use and saving valuable nursing time and costs.
For Avanos Medical, a company focused on delivering medical technologies that improve patient care and clinical outcomes, this purchase represents a significant move to enhance its product portfolio and strengthen its market presence in vascular access and infusion therapy. The acquisition provides Avanos with direct access to Nexus's established anti-reflux technology, which directly addresses significant challenges in infusion safety and efficiency. Integrating Nexus's clinically proven technology is expected to create substantial synergies, meeting the evolving demands for safer and more effective patient care solutions across various healthcare settings.
This strategic transaction firmly establishes Avanos Medical's dedication to leading innovation in patient safety. The combination of Avanos Medical's established market reach and Nexus Medical's specialized, occlusion-preventing technology is anticipated to significantly strengthen the combined entity's ability to drive progress in infusion therapy. This will ultimately improve the standard of care for patients requiring intravenous treatment and enhance operational efficiencies for healthcare providers globally.